Methoxyflurane – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Methoxyflurane is an early halogenated ether that had a remarkable second life. As a general anesthetic (Penthrane, 1962) it was withdrawn in 1974 after dose-dependent nephrotoxicity was traced to intrarenal defluorination producing high plasma fluoride that blocks ascending-limb chloride transport. Forty years later it returned in a low-dose hand-held inhaler format (Penthrox, the green whistle) for procedural analgesia, approved in Australia and re-approved in the EU and UK in 2018. The 3 mL inhaler dose for fracture reduction or dressing changes delivers fluoride exposures orders of magnitude below the historical nephrotoxic threshold. Mechanism includes the standard volatile anesthetic profile plus pronounced TRPA1 modulation that contributes to the analgesia. A genuinely novel sub-anesthetic application of an old molecule. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Old withdrawn anesthetic reborn as low-dose procedural analgesic; niche clinical utility, limited research frontier value

Look, methoxyflurane is a genuinely interesting case study in pharmacological rehabilitation, but it’s not a research priority for most bench investigators right now. The compound is old — developed in the 1950s, clinically deployed in 1962, withdrawn as a general anesthetic in 1974 after it became clear that prolonged high-dose use produced serious nephrotoxicity via CYP2E1-mediated intrarenal defluorination. The mechanism of that injury is well-characterized: inorganic fluoride accumulates at concentrations sufficient to block ascending limb chloride transport, producing vasopressin-resistant polyuria and high-output renal failure. Thats decades-old toxicology with nothing much left to discover.

The Penthrox reintroduction is real and clinically respectable. The insight that sub-anesthetic doses through a handheld disposable inhaler can produce useful procedural analgesia without approaching the fluoride nephrotoxicity threshold was genuinely clever, and the EU and UK regulatory approvals in 2018 — plus the much longer-running Australian approval — reflect multi-site clinical validation in emergency medicine settings. The trial literature on extremity fractures and dressing changes is modest but honest. This isnt marketing.

Here’s what we like: the TRPA1 modulation angle. Most of the volatile anesthetic research conversation focuses on the canonical GABA-A and NMDA profile of halogenated ethers, but methoxyflurane has a disproportionate TRPA1 interaction that may be meaningfully responsible for the analgesic phenotype at sub-anesthetic exposures. That’s a pharmacologically distinct story from just partially sedating someone, and it makes the compound a legitimate probe for TRPA1’s contribution to acute and procedural pain. We don’t think that story is fully written. The CYP2E1 defluorination pathway also gives it niche value for investigators modeling halogenated compound metabolism and fluoride-mediated renal injury.

What we don’t like: the novelty floor is very low. The mechanism is saturated territory, the toxicology is settled, and the Penthrox clinical program — while real — is procedural analgesia in an emergency department, not frontier pharmacology. The blood-gas partition coefficient of 13 (highest in its class) makes it genuinely awkward as a bench research tool. You cannot rapidly titrate it, standardizing inhalational exposure in a controlled experimental system is non-trivial, and the compound’s physical properties create reproducibility headaches that other TRPA1 probes don’t share.

Honestly, methoxyflurane sits in a narrow utility lane: TRPA1 probe work in pain biology, acute procedural analgesia modeling, or nephrotoxicity mechanism studies using the CYP2E1 pathway as a fluoride-production model. Those are specific and real, but the research frontier value is low. If your program isn’t explicitly about inhalational analgesia or TRPA1 biology, there are more compelling places to direct bench time right now.

Novelty: 28
Mechanism promise: 40
In-category differentiation: 38
Evidence quality: 63
Translational signal: 60
Research bench value: 28

Rationale Methoxyflurane scores on evidence and translational signal because Penthrox is a real approved product with multi-site trial data, but novelty and bench value drag heavily — it’s a 1950s compound with well-understood mechanism and toxicology; the TRPA1 angle is the only genuinely interesting hook for a modern research program.

Halogenated ether volatile general anesthetic and analgesic

An early halogenated ether withdrawn for nephrotoxicity but reintroduced in low-dose hand-held inhaler format (Penthrox) for procedural analgesia.

Abstract

Methoxyflurane (2,2-dichloro-1,1-difluoroethyl methyl ether; CAS 76-38-0; molecular formula C3H4Cl2F2O; molecular weight 164.97) is a halogenated methyl ethyl ether developed by Ross Terrell in the 1950s and introduced clinically by Abbott in 1962 (Penthrane). The agent was widely used as a general anesthetic through the early 1970s before reports of dose-dependent nephrotoxicity led to withdrawal as a primary anesthetic in 1974 in the United States. The mechanism of methoxyflurane nephrotoxicity is intrarenal defluorination by CYP2E1 producing inorganic fluoride at concentrations sufficient to inhibit ascending limb chloride transport (high-output renal failure with vasopressin-resistant polyuria, the classical methoxyflurane nephropathy). The threshold for clinically apparent renal injury is approximately 50 micromolar plasma fluoride and is exceeded by general anesthetic doses (MAC 0.16 percent for many hours) but not by the brief, low-dose inhaler format reintroduced as Penthrox in Australia and re-approved in the EU and UK in 2018 for procedural analgesia. The Penthrox formulation delivers approximately 3 mL methoxyflurane through a hand-held disposable inhaler (the green whistle), producing analgesia for procedural pain (extremity injuries, dressing changes, fracture reduction) at exposure levels orders of magnitude below the historical nephrotoxic threshold. The blood-gas partition coefficient is 13, the highest in the class, corresponding to slow induction and prolonged emergence; the clinical Penthrox dose is sub-anesthetic and produces only analgesia and mild sedation. Mechanism includes the standard halogenated ether profile plus pronounced TRPA1 modulation contributing to the analgesic phenotype.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1306Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.